Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reissued their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE) in a research note published on Monday,Benzinga reports. They currently have a $46.00 price target on the stock.

A number of other equities analysts have also recently weighed in on the company. Wells Fargo & Company initiated coverage on Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price target for the company. Raymond James Financial initiated coverage on Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective on the stock. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $48.57.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock opened at $45.06 on Monday. The firm has a 50-day simple moving average of $44.00 and a two-hundred day simple moving average of $34.85. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $49.25. The company has a market cap of $2.17 billion, a P/E ratio of -2.16 and a beta of 4.46.

Insider Buying and Selling

In other Maze Therapeutics news, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.02, for a total transaction of $690,300.00. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 200,000 shares of company stock worth $8,254,792.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds have recently modified their holdings of MAZE. Janus Henderson Group PLC lifted its stake in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. grew its stake in Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares in the last quarter. Marshall Wace LLP raised its holdings in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after acquiring an additional 758,104 shares during the last quarter. Caligan Partners LP acquired a new stake in Maze Therapeutics in the 4th quarter valued at about $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics in the 3rd quarter worth approximately $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.